Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C

Gut

Volumn 63, Issue 1, 2014, Pages 161-169

  Rotman, Yaron ^a   Noureddin, Mazen ^a   Feld, Jordan J ^a   Guedj, Jeremie ^b,c,d   Witthaus, Michael ^a   Han, Hwalih ^a   Park, Yoon J ^a   Park, Su Hyung ^a   Heller, Theo ^a   Ghany, Marc G ^a   Doo, Edward ^a   Koh, Christopher ^a   Abdalla, Adil ^a   Gara, Naveen ^a   Sarkar, Souvik ^a   Thomas, Emmanuel ^a   Ahlenstiel, Golo ^a   Edlich, Birgit ^a   Titerence, Rachel ^a   Hogdal, Leah ^a   Rehermann, Barbara ^a   Dahari, Harel ^b,e,f   Perelson, Alan S ^b   Hoofnagle, Jay H ^a   Liang, T Jake ^a   more..

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON STIMULATED GENE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; MIDDLE AGED; MONOTHERAPY; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VIRAL KINETICS;

HEPATITIS C; INTERFERON-ALPHA;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TRANSCRIPTOME; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84889635179     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303852     Document Type: Article

References (27)

1. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44.
2. Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-5.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
4. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
5. Brillanti S, Mazzella G, Roda E. Ribavirin for chronic hepatitis C: and the mystery goes on. Dig Liver Dis 2011;43:425-30.
6. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72. (Pubitemid 41191673)
7. Thomas E, Ghany MG, Liang TJ. The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antivir Chem Chemother 2012;23:1-12.
8. Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011;53:32-41.
9. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007;46:1548-63. (Pubitemid 350155537)
10. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25. (Pubitemid 351355126)
11. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met 1995;57:289-300.
12. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44. (Pubitemid 40712193)
13. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405-8.
14. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology 2012;55:749-58.
15. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.
16. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-14. (Pubitemid 38298318)
17. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7. (Pubitemid 27328328)
18. Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003;38:66-74. (Pubitemid 36775797)
19. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007;47:23-30. (Pubitemid 46817685)
20. Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602-11, 11 e1.
21. Yang J, Huang J, Dasgupta M, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 2010;107:21499-504.
22. Sarasin-Filipowicz M, Wang X, Yan M, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/ UBP43. Mol Cell Biol 2009;29:4841-51.
23. Slavenburg S, Huntjens-Fleuren HW, Dofferhoff TS, et al. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit 2011;33:40-4.
24. Lanford RE, Guerra B, Lee H, et al. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006;43:961-72. (Pubitemid 43724621)
25. Ji X, Cheung R, Cooper S, et al. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003;37:610-21. (Pubitemid 36258783)
26. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007;81:3391-401. (Pubitemid 46456648)
27. Brillanti S, Buonfiglioli F, Feletti V, et al. Ribavirin priming enhances efficacy of chronic hepatitis C re-treatment in patients who had not responded to previous combination therapy. Hepatology 2009;50:317A.